Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for
which no effective medical therapy is available or recommended. We will evaluate the use of
cabergoline in a clinical trial, in order to define the efficacy of this treatment in
nonfunctioning pituitary adenoma.